Small cell lung cancer is an aggressive, rapidly growing subtype of lung cancer that tends to metastasize early. It is biologically and clinically distinct from non-small cell lung cancer.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
Soft tissue sarcoma pipeline activity includes 70+ companies and 75+ therapies. A phase II ADI-PEG 20 trial with gemcitabine and docetaxel was designed for sarcomas, while other 2026 studies span synovial sarcoma and unresectable advanced disease.
Zai Lab's Q1 2026 revenue fell 6% to $99.6 million, missing expectations, while EPS beat at -$0.05. The company highlighted Zoci intracranial response data and expects three pivotal trials by year-end 2026.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Researchers identified three distinct molecular phenotypes of small cell lung cancer that could help stratify patients for targeted therapy. Only patients with ANXA1Low infiltrated phenotype derived significant survival benefit from chemotherapy plus immune checkpoint inhibitors. Separate research found that targeting epigenetic regulators like PRC2 and G9a/GLP could enhance treatment efficacy.
GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.
Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07778316 |
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) |
RECRUITING | PHASE3 |
| NCT07759856 |
NK Cells Plus ICI for SCLC Maintenance |
RECRUITING | PHASE2 |
| NCT07752875 |
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07707895 |
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07670442 |
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy |
NOT_YET_RECRUITING | |
| NCT07636226 |
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07559929 |
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07557225 |
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors |
RECRUITING | NA |
| NCT07551635 |
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07550049 |
Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology |
NOT_YET_RECRUITING |
